PUMA BIOTECHNOLOGY INC Stock Prediction
AI-powered sentiment analysis and prediction trends for PBYI, updated each market day.
PBYI AI Sentiment
AI sees no strong directional signal for PUMA BIOTECHNOLOGY INC stock over the next 10 market days.
Prediction date: Oct. 9, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About PUMA BIOTECHNOLOGY INC
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Sector
Exchange
Market Cap
$507,941,449
Cap Tier
Employees
179
Headquarters
LOS ANGELES, CA
Listed Since
March 21, 2012
PBYI Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PBYI Volatility
PUMA BIOTECHNOLOGY INC has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
